AnaptysBio
Patents, Design & Utilities
Last updated:
List of all AnaptysBio patents 21 in total
| Status | Patent |
|---|---|
Application | Utility: PD-1 AGONIST AND METHOD OF USING SAME Filling date: 6 Sep 2025 Issue date: 28 Jul 2022 |
Application | Utility: ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) Filling date: 6 Sep 2025 Issue date: 2 Jun 2022 |
Application | Utility: ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 5 May 2022 |
Application | Utility: Antibodies Directed Against Programmed Death-1 (PD-1) Filling date: 6 Sep 2025 Issue date: 24 Mar 2022 |
Application | Utility: ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R) Filling date: 6 Sep 2025 Issue date: 16 Dec 2021 |
Grant | Utility: Antibodies directed against programmed death-1 (PD-1) Filling date: 6 Sep 2025 Issue date: 26 Oct 2021 |
Grant | Utility: Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) Filling date: 6 Sep 2025 Issue date: 28 Sep 2021 |
Application | Utility: Antibodies Directed Against Programmed Death-1(PD-1) Filling date: 6 Sep 2025 Issue date: 3 Jun 2021 |
Application | Utility: Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3) Filling date: 6 Sep 2025 Issue date: 1 Apr 2021 |
Application | Utility: ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) Filling date: 6 Sep 2025 Issue date: 11 Feb 2021 |
Grant | Utility: Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33) Filling date: 6 Sep 2025 Issue date: 17 Nov 2020 |
Grant | Utility: Antibodies directed against lymphocyte activation gene 3 (LAG-3) Filling date: 6 Sep 2025 Issue date: 17 Nov 2020 |
Grant | Utility: Antibodies directed against programmed death-1 (PD-1) Filling date: 6 Sep 2025 Issue date: 11 Aug 2020 |
Application | Utility: ANTI-IL-33 THERAPY FOR ATOPIC DERMATITIS Filling date: 6 Sep 2025 Issue date: 30 Jul 2020 |
Application | Utility: ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) Filling date: 6 Sep 2025 Issue date: 14 May 2020 |
Application | Utility: ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R) Filling date: 6 Sep 2025 Issue date: 19 Mar 2020 |
Grant | Utility: Antibodies directed against interleukin 36 receptor (IL-36R) Filling date: 6 Sep 2025 Issue date: 7 Jan 2020 |
Grant | Utility: Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) Filling date: 6 Sep 2025 Issue date: 17 Dec 2019 |
Application | Utility: ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) Filling date: 6 Sep 2025 Issue date: 19 Sep 2019 |
Application | Utility: ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) Filling date: 6 Sep 2025 Issue date: 22 Aug 2019 |
Application | Utility: ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH- 1 (PD-1) Filling date: 6 Sep 2025 Issue date: 22 Aug 2019 |
Showing 1 to 21 of 21 patents.